Company intelligence / Profile preview

Jilin Maifeng Biological Pharmaceutical

Changchun, Jilin, China

Ownership: Private
Development stage: Other

Overview

Jilin Maifeng Biological Pharmaceutical is a Chinese biotechnology company specializing in the research, development, and production of human vaccines. As a key subsidiary of Changchun BCHT Biotechnology, the company is primarily recognized for its large-scale production of the freeze-dried human rabies vaccine (Vero cell). Operating out of Changchun, Jilin Province, Maifeng maintains high-standard GMP manufacturing facilities to supply the domestic Chinese market. Its core business focuses on infectious disease prevention through advanced biological manufacturing processes and cell culture technologies.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Beyond the preview

Go deeper on Jilin Maifeng Biological Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Maifeng Biological Pharmaceutical.

Explore the full profile